Skip to content

Comparison of Remimazolam and Dexmedetomidine for Intraoperative Sedation

Comparison of Remimazolam and Dexmedetomidine for Intraoperative Sedation During Regional Block

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05447507
Enrollment
104
Registered
2022-07-07
Start date
2022-07-08
Completion date
2022-10-26
Last updated
2022-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orthopedic Disorder

Brief summary

The purpose of this study is to compare the sedation efficacy of dexmedetomidine and remimazolam for intraoperative sedation during regional block.

Interventions

DRUGRemimazolam

0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.5\ 1.0 mg/kg/h continuous infusion

DRUGDexmedetomidine

1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2\ 0.7 mcg/kg/h continuous infusion

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Patient scheduled for lower extremity surgery under regional anesthesia, aged 19-70, of ASA class I or II.

Exclusion criteria

* Patient refusal * Contraindications to regional or neuraxial anesthesia (patient refusal, increased intracranial pressure, infection at puncture site, underlying neurologic disease, severe hypovolemia, aortic or mitral stenosis, thrombocytopenia or coagulopathy) * Contraindications to dexmedetomidine or remimazolam administration * Allergy to dexmedetomidine or remimazolam * Baseline MOAA/S score of 4 or less * Pregnancy * Other conditions considered unsuitable by the investigators

Design outcomes

Primary

MeasureTime frame
Number of rescue sedative doses administeredIntraoperative period

Secondary

MeasureTime frameDescription
Incidence of intraoperative hypotension (mean blood pressure lower than 65 mmHg or systolic blood pressure lower than 80% of baseline)Intraoperative period
Incidence of intraoperative hypertension (systolic blood pressure higher than 120% of baseline)Intraoperative period
Incidence of respiratory depression (respiratory rate lower than 8 per minute)Intraoperative period
Incidence of hypoxia (oxygen saturation detected by pulse oxymetry less than 93%)Intraoperative period
MOAA/S score (Modified Observer's Assessment of Alertness and Sedation, 0=unarousable, 5=alert)Intraoperative period
Intraoperative PSi (Patient State index)Intraoperative period
Electroencephalogram data (alpha, beta, delta, theta waves)Intraoperative period
Incidence of intraoperative bradycardia (heart rate lower than 45 bpm)Intraoperative period
Oxygen supply at the post-anesthesia care unitPost-anesthesia care period (immediate post-operative period)
Incidence of postoperative deliriumImmediately after the surgery, up to 5 days after surgery
Incidence of nausea/vomitingIntraoperative period and post-anesthesia care period (immediate post-operative period)
Postoperative spinal anesthesia block levelPostoperative period, up to 12h hours after end of surgery
Duration of stay in the post-anesthsia care unit(PACU)Immediate postoperative period
Patient satisfaction (numerical rating scale of 0~10)Immediately after the surgery, up to 5 days after surgery0 Not at all satisfied, 10 very satisfied
Serum CRP levelPreoperative baseline and second postoperative day
Time to reach MOAA/S = 5 after end of drug infusionIntraoperative period and post-anesthesia care period (immediate post-operative period)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026